This page has been archived on the Web
Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact us to request a format other than those available.
EFFIENT (prasugrel hydrochloride) - Association with Increased Risk of Bleeding in Patients Treated in Hospital for Certain Types of Heart Attacks - For the Public
- Starting date:
- January 17, 2014
- Posting date:
- January 17, 2014
- Type of communication:
- Public Communication
- Subcategory:
- Drugs
- Source of recall:
- Health Canada
- Issue:
- Important Safety Information
- Audience:
- General Public
- Identification number:
- RA-37615
This is duplicated text of a letter from Eli Lilly Canada Inc. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
PUBLIC COMMUNICATION - Health Canada Endorsed Important Safety Information on EFFIENT (prasugrel hydrochloride)
January 17, 2014
Subject: Association of EFFIENT® (prasugrel hydrochloride) with increased risk of bleeding in patients treated for certain types of heart attacks at the hospital.
Eli Lilly Canada Inc. in collaboration with Health Canada would like to inform patients and their caregivers of important safety information about EFFIENT® (prasugrel hydrochloride). EFFIENT® is an antiplatelet medication which lowers the ability of blood to clot. A doctor can start EFFIENT® at the hospital around the time of a procedure to open a blocked heart artery in patients with certain types of heart attacks.
- Patients treated for certain types of heart attacks at the hospital are at an increased risk of bleeding when EFFIENT® is started before looking at the heart arteries with an angiogram (compared to when EFFIENT® was given after looking at the heart arteries).
- Doctors have been advised to consider this risk when starting treatment with EFFIENT® for certain types of heart attacks.
- There is no additional harm to people who are already taking EFFIENT®. Do not stop taking EFFIENT® without discussing with your doctor. Stopping EFFIENT® may increase the chance of having a heart attack.
This communication is posted on the Healthy Canadians Web site and on the Eli Lilly Canada Inc. Web site.
Managing marketed health product-related side effects depends on health care professionals and consumers reporting them. Any case of serious or unexpected side effects in patients receiving EFFIENT® should be reported to Eli Lilly Canada Inc. or Health Canada.
Eli Lilly Canada Inc.
Toronto, Ontario
1-888-545-5972
You can report any suspected side effect associated with the use of health products to Health Canada by:
- Calling toll-free at 1-866-234-2345; or
- Visiting MedEffect Canada's Web page on Adverse Reaction Reporting for information on how to report online, by mail or by fax.
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Sincerely,
original signed by
Doron Sagman, MD, FRCPC
Vice President, Research & Development
Eli Lilly Canada Inc.